3Clinical Trials. gov. An evaluation of the effects of LC1699 on cortisol in patients with hypertension [ EB/OL ]. ( 2010 - 02 - 22) [ 2010 - 05-05]. http ://clinicahrials. gov/ct2/show/NCT00817414.
4Clinical Trials. gov. Efficacy and safety of TAK-536 in subjects with essential hypertension [ EB/OL]. (2009 - 01 - 24) [ 2010 - 05 - 06 ]. http://clinicaltrials, gov/ct2/show/NCTO07595519. term = TAK-536&rank = 1.
6Gilead Sciences,Inc. Phase III study of Gilead's darusentan for resistant hypertension meets primary endpoints[EB/OL]. (2009 - 04 - 02 ) [2010 - 05 - 06]. http://www. gilead. com/pr_ 1273012.
7Gilead Sciences,Inc. Second pivotal phase III study of Gilead's darusentan for resistant hypertension misses primary endpoints [EB/OL]. (2009-12-06) [2010-05 -06]. http://investors. gilead, corn/phoenix, zhtmt? c = 69964&p = irol-newsArti- cle &ID = 1365747&highlight =.
8MARKI HP, BINGGELI A, BITTNER B, et al. Piperidine renin inhibitors : from leads to drug candidates[J]. II Farmaco( S0014- 827X) ,2001,56(1 -2) :21 -27.
9BEZENCON O,BUR D,WELLER T,et al. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors [ J ]. J Med Chem, 2009,52 ( 12 ) : 3689 - 3702.
10ClinicalTrials. gov. A dose-ranging study of the safety and efficacy of ADX415 in the treatment of essential hypertension [EB/ OL]. ( 2008 - 12 - 16 ) [ 2010 - 02 - 20 ]. http ://clinieahrials- feeds. org/cllnical-trials/show/NCT00779181.
